
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings is a promising clinical-stage genetic medicines company with a strategic pipeline that includes treatments for diseases with high unmet need, strong manufacturing capabilities, and proprietary gene therapy platforms. The company's recent data update on its AAV2-hAQP1 gene therapy for radiation-induced xerostomia showed sustained clinical benefit and secured FDA Breakthrough Therapy Designation, providing strong support for its potential approval and commercialization. With the recent reacquisition of its botaretigene sparoparvovec program for X-linked retinitis pigmentosa (XLRP), the company is well-positioned for near-term regulatory progress and commercial launch, supported by a strong balance sheet and potential non-dilutive financing opportunities. However, risks to the outlook include clinical execution, regulatory uncertainties, IP risk, and long-term pricing pressure. Overall, the current pipeline and financial prospects support a positive outlook on MeiraGTx Holdings' stock.
Bears say
MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company operating in a highly competitive and complex market with significant regulatory uncertainties, IP risks, and pricing pressures. Although the company is making progress in aligning with sustainability principles and has a promising pipeline development, it still faces significant risks in clinical program execution, competition, and delays in obtaining regulatory approvals. Therefore, the outlook for the MeiraGTx Holdings stock remains negative in the near term.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares